SOPHiA GENETICS (NASDAQ:SOPH) Chairman Sells $326,598.36 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 40,172 shares of the business’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $8.13, for a total value of $326,598.36. Following the completion of the transaction, the chairman directly owned 3,395,650 shares of the company’s stock, valued at approximately $27,606,634.50. The trade was a 1.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Thursday, September 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.66, for a total value of $65,110.00.
• On Monday, August 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.61, for a total value of $64,685.00.
• On Friday, August 7th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.23, for a total value of $144,600.00.
• On Tuesday, August 4th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.92, for a total value of $138,400.00.
• On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.63, for a total transaction of $132,600.00.
• On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.29, for a total transaction of $153,356.49.
• On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.62, for a total transaction of $47,770.00.

SOPHiA GENETICS Stock Down 3.1%

Shares of NASDAQ:SOPH traded down $0.23 during midday trading on Wednesday, reaching $7.15. 432,750 shares of the company were exchanged, compared to its average volume of 308,157. SOPHiA GENETICS SA has a fifty-two week low of $3.75 and a fifty-two week high of $8.98. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. The stock has a fifty day simple moving average of $7.82 and a two-hundred day simple moving average of $6.12. The firm has a market cap of $599.81 million, a PE ratio of -6.22 and a beta of 0.95.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The company had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. As a group, sell-side analysts forecast that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of institutional investors have recently added to or reduced their stakes in the company. AWM Investment Company Inc. acquired a new position in SOPHiA GENETICS during the second quarter worth $9,809,000. Principal Financial Group Inc. grew its position in shares of SOPHiA GENETICS by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after acquiring an additional 9,800 shares during the period. Hodges Capital Management Inc. acquired a new position in shares of SOPHiA GENETICS during the 1st quarter worth about $2,157,000. Sei Investments Co. acquired a new position in shares of SOPHiA GENETICS during the 1st quarter worth about $1,772,000. Finally, 1492 Capital Management LLC raised its holdings in shares of SOPHiA GENETICS by 8.4% in the 1st quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock valued at $1,117,000 after purchasing an additional 17,406 shares during the period. 31.59% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. BTIG Research raised their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, HC Wainwright lifted their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.